Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPRG.L Regulatory News (PRG)

  • There is currently no data for PRG

Non-Board Appointments

9 May 2005 07:01

Premier Research Group09 May 2005 For Immediate Release 9 May 2005 Premier Research appoints Anthony Orlando and Bruce C Stouch to New Senior Management Positions Premier Research Group plc (AIM: PRG) ("Premier Research", "Company" or "Group"), the international pharmaceutical services group today announces theappointment of -- Anthony Orlando, Ph.D and Bruce C Stouch Ph.D to seniormanagement positions in Premier Research. Dr Anthony Orlando, Ph.D has joined the US Operations of Premier Research Groupplc in the new position of Executive Director, Data Operations. Dr. Orlandobrings an exceptional background in Biostatistics and Data Management over thepast thirty years including key roles in pharmaceutical companies, the NationalCenter for Toxicological Research/FDA and at major contract researchorganizations. He most recently joined the company from his position as VicePresident, Biostatistics at SFBC New Drug Services. Dr. Orlando holds a Ph.D. inBiometry from Yale University, has co-authored many papers in his area ofexpertise and has supported several drug NDAs for a variety of indications. Hewill be responsible for US data management, programming and biostatistics forPremier Research. In addition to Dr. Orlando's position, Premier Research also is pleased toannounce that Bruce C. Stouch, Ph.D. has taken the international position ofChief Scientific Officer for the company. In Dr. Stouch's new role, he will leadthe company's efforts supporting expert FDA/statistical clinical design andanalysis capabilities. He will also establish and expand the company's newinitiative into Bayesian monitoring and analysis methods. Dr. Stouch has over15 years of biostatistics experience in pharmaceuticals. For 12 years, Dr. Stouch held position of Director of Biostatistics andScientific Data Management at Johnson & Johnson in Exton, PA, where he wasresponsible for strategic development and implementation of pharmacoeconomicmodels of emerging technologies in several therapeutic areas. Dr. Stouch hasbeen involved in over two dozen publications and acknowledgements. He holds anacademic appointment at the Philadelphia College of Medicine as Director,Biostatistics and Clinical Epidemiology. Dr. Stouch received his Ph.D. inBiostatistics and Epidemiology from Jefferson Medical College in 1997 through aprogram sponsored by Johnson & Johnson, and trained in post-graduate studiesfrom Temple University, Jefferson Medical College, and Harvard School of PublicHealth. Dr Simon Yaxley, CEO of Premier Research Group plc, commented: "We are proud andpleased to announce the significant strengthening of our data management andstatistics capabilities in the US Operations, we also believe that Tony andBruce place our company at the forefront of trial design, monitoring andanalysis methods worldwide." About Premier Research Premier Research Group plc is a contract research organisation focused on thedesign, management and reporting of all phases of clinical trials on behalf ofpharmaceutical and biotechnology companies. The Company specialises in oncology,central nervous system, paediatrics and anti-infectives. For Further information, please contact: Premier Research Group Plc Tel: 01344 458 311Dr Simon Yaxley, Chief Executive Buchanan Communications Tel: 020 7466 5000Lisa Baderoon/Diane Stewart/Rebecca Skye Dietrich This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
11th Mar 20082:42 pmRNSRule 8.3- Premier Research Gp
11th Mar 20082:39 pmPRNRule 8.3 - Premier Research
11th Mar 20089:16 amRNSEPT Disclosure
10th Mar 20081:29 pmRNSRule 8.3- Premier Research
10th Mar 20089:19 amRNSEPT Disclosure
7th Mar 20088:12 amRNSEPT Disclosure
6th Mar 20081:00 pmRNSRule 8.3- Premier Research Gp
6th Mar 200811:54 amRNSHolding(s) in Company
6th Mar 20089:36 amRNSEPT Disclosure
5th Mar 20081:58 pmRNSRule 8.3- Premier Research Gp
5th Mar 20081:30 pmRNSRule 8.3- Premier Research
5th Mar 200811:32 amRNSEPT Disclosure
4th Mar 20083:20 pmRNSEPT Disclosure-Amendment
4th Mar 20082:06 pmPRNRule 8.3 - Premier Research
4th Mar 200811:15 amRNSEPT Disclosure
3rd Mar 20083:06 pmRNSRule 8.3- Premier Research
3rd Mar 20082:24 pmPRNRule 8.3 - Premier Research plc
3rd Mar 200811:31 amRNSEPT Disclosure
29th Feb 20082:41 pmPRNRule 8.3 - Premier Research
29th Feb 20082:26 pmRNSRule 8.3- Premier Research
29th Feb 20089:44 amRNSEPT Disclosure
28th Feb 20081:37 pmRNSRule 8.3- Premier Research
28th Feb 20088:50 amRNSEPT Disclosure
28th Feb 20087:00 amRNSTrading Update
27th Feb 20083:04 pmRNSRule 8.3- Premier Research
27th Feb 20089:25 amRNSEPT Disclosure
26th Feb 20083:27 pmRNSRule 8.3- (Premier Research)
26th Feb 200810:51 amRNSRule 8.3- Premier Research
26th Feb 20088:18 amRNSEPT Disclosure
25th Feb 20083:24 pmRNSRule 8.3- Premier Research
25th Feb 20082:50 pmRNSRule 8.3- Premier Research
25th Feb 20089:06 amRNSEPT Disclosure
22nd Feb 20083:30 pmRNSRule 8.3- Premier Research
22nd Feb 20089:04 amRNSEPT Disclosure
21st Feb 20083:14 pmRNSRule 8.3- Premier Research
21st Feb 200811:31 amRNSEPT Disclosure
20th Feb 20082:34 pmRNSRule 8.3- Premier Research
20th Feb 20088:40 amRNSEPT Disclosure
19th Feb 20081:49 pmRNSRule 8.3- Premier Research
19th Feb 20088:48 amRNSEPT Disclosure
18th Feb 20082:49 pmRNSRule 8.3- Premier Research
18th Feb 20089:35 amRNSEPT Disclosure
15th Feb 20082:24 pmRNSRule 8.3- Premier Research
15th Feb 200812:48 pmRNSRule 8.3- Premier Research
15th Feb 200812:31 pmRNSRule 8.3- Premier Research
15th Feb 20089:24 amRNSEPT Disclosure
14th Feb 200810:48 amRNSRule 8.3- Premier Research
14th Feb 200810:19 amRNSRule 8.3- Premier Research
14th Feb 20089:18 amRNSEPT Disclosure
13th Feb 20083:13 pmRNSRule 8.3 - Premier Research

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.